Antifungal Drug Design and Structural Optimization

Antifungal drug design has evolved from broad-spectrum natural products to precision-engineered small molecules that target fungal-specific pathways. Central to this endeavour is inhibition of lanosterol 14α-demethylase (CYP51), a key enzyme in ergosterol biosynthesis essential for fungal cell membrane integrity. Structural optimisation employs systematic variation of heterocyclic cores, substitution patterns and linker domains to enhance potency, selectivity and pharmacokinetic properties while minimising host toxicity. Integration of structure–activity relationship (SAR) studies, molecular docking, molecular dynamics and absorption–distribution–metabolism–excretion–toxicity (ADME/T) profiling has accelerated lead identification and refinement. Emerging scaffolds such as triazole–thiazolidine hybrids, quinoxaline–triazole conjugates and metal–azole complexes demonstrate improved activity against resistant strains and biofilms. These advances address the growing global burden of invasive mycoses, offering prospects for safer, more effective therapies in immunocompromised populations.

Research from Nature Portfolio

Recent work has explored potassium N-acylhydrazinecarbodithioate salts and their aminotriazole-thione derivatives as antidermatophyte agents. One lead compound exhibited potent inhibition of Trichophyton and Microsporum species at non-cytotoxic concentrations. Scanning and transmission electron microscopy revealed disruption of mycelial networks and spore ultrastructure, while RNA sequencing uncovered broad activation of fungal stress response pathways. These findings highlight a novel chemotype for treating dermatophyte infections and provide a foundation for structure-guided optimisation.

Antifungal Drug Design and Structural Optimization publication trend

The graph below shows the total number of articles in antifungal drug design and structural optimization across all publications each year (not limited to Nature Index journals).

Technical terms

Minimum inhibitory concentration (MIC): lowest concentration of an antifungal agent that prevents visible fungal growth.

Structure–activity relationship (SAR): correlation between chemical modifications and resulting changes in biological activity.

Molecular docking: computational method predicting how a small molecule binds to a protein target.

Lanosterol 14α-demethylase (CYP51): fungal enzyme involved in ergosterol synthesis and primary target of azole antifungals.

Biofilm: structured microbial community attached to a surface and embedded in a protective extracellular matrix.

References

1. Evaluation of the antidermatophytic activity of potassium salts of N-acylhydrazinecarbodithioates and their aminotriazole-thione derivatives. Scientific Reports (2024).
2. Design, synthesis and in vitro biological studies of novel triazoles with potent and broad-spectrum antifungal activity. Journal of Enzyme Inhibition and Medicinal Chemistry (2023).
3. Synthesis and Biological Evaluation of a Series of New Hybrid Amide Derivatives of Triazole and Thiazolidine-2,4-dione. Pharmaceuticals (2024).
4. Synthesis, Antifungal Activities, Molecular Docking and Molecular Dynamic Studies of Novel Quinoxaline-Triazole Compounds. ACS Omega (2023).